Amalya Sargsyan, VP, Research and Intelligence of OncoDaily, shared on LinkedIn:
“OncoDaily Sarcoma Grand Rounds – ESMO 2026 Edition has kicked off!
Chaired by Robin Jones and Javier Martin-Broto, with faculty Emanuela Palmerini and Italiano Antoine, bringing together sarcoma experts for an exciting scientific discussion.
Robin Jones opened with chondrosarcoma, exploring the limited benefits of TKIs and immune checkpoint inhibitors, emerging IMMUNOSARC data, and IDH1-targeted therapies, including ivosidenib and olutasidenib, CHONdragon trial with Ozekibart.
We also heard from Pan Pantziarka, the European Director of the Sarcoma Foundation of America, about the barriers slowing sarcoma clinical trials and what needs to change to accelerate research and patient access.
Are we getting closer to meaningful breakthroughs in sarcoma treatment?
And this is just the beginning!
OncoDaily Sarcoma is coming soon! A new branch of the OncoDaily family dedicated to advancing sarcoma research, education, and collaboration.
Stay tuned!”
You can also read:
OncoDaily Grand Rounds at ESMO 2026: Sarcoma Edition
